Correction to: Drugs & Therapy Perspectives 2018 34(8):351–357 https://doi.org/10.1007/s40267-018-0536-9
The article Osimertinib as first-line therapy in advanced NSCLC: a profile of its use, written by Lesley J. Scott, was originally published Online First without open access. After publication in volume 34, issue 8, pages 351–357, AstraZeneca Pharmaceuticals LP requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AstraZeneca Pharmaceuticals LP. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Scott, L.J. Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect 35, 50 (2019). https://doi.org/10.1007/s40267-018-0594-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-018-0594-z